News from NYU Langone Health
NYU Langone Health Launches Digital Pathology Program. (Becker’s Hospital Review)
Becker’s Hospital Review (10/14) NYU Langone Health has introduced a digital pathology program, enabling pathologists to analyze high-definition digital images instead of physical slides for diagnosing diseases, and has recruited 24 digital pathology coordinators to support this initiative.
Hospitals With Highest, Lowest 30-Day Mortality Rates For Heart Attack Patients. (Becker’s Hospital Review)
Becker's Hospital Review (10/14) NYU Langone Health “had the lowest 30-day mortality rate for heart attack patients in the U.S. between July 1, 2020 and June 30, 2023, according to CMS data released July 31.
Human Sense Of Smell Is Faster Than Previously Thought, New Study Suggests. (CNN)
CNN (10/14) Dmitry Rinberg, PhD, a professor in the Department of Neuroscience and Physiology, contributed to an editorial in Nature Human Behaviour discussing a new study that reveals the human sense of smell can discern odor sequences with a latency as short as 60 milliseconds, challenging previous research suggesting a 1,200-millisecond timing.
Also reporting is HealthDay (10/15).
19 Health Systems With Credit Rating Upgrades. (Becker’s Hospital Review)
Becker’s Hospital Review (10/14) NYU Langone Health’s credit rating was upgraded to “A1” from “A2” by Moody’s, with the ratings agency attributing the upgrade to the system’s anticipated sustained strong and consistent operating performance and revenue growth compared to peers, bolstered by its robust market position and highly effective and disciplined leadership.
Dr Lau On Tarlatamab As Maintenance Therapy In Extensive-Stage SCLC. (OncLive)
OncLive (10/14) Sally Lau, MD, assistant professor, Department of Medicine, and a thoracic medical oncologist at NYU Langone’s Perlmutter Cancer Center, discussed the phase 1b DeLLphi-303 study, which assessed tarlatamab-dlle in combination with a PD-L1 inhibitor for extensive-stage small cell lung cancer (ES-SCLC), revealing a 62.5% disease control rate with tarlatamab plus durvalumab and atezolizumab, with median disease control durations exceeding 9 months and 7.2 months, respectively, and a median progression-free survival rate at 9 months of 5.3 and 5.6 months, suggesting improved outcomes over PD-L1 inhibition alone, alongside a favorable overall survival trend at 91.8%, though Lau indicates further studies are needed.
Oral Bacteria May Be Biomarker To Predict Risk For Head, Neck Cancers. (Healio)
Healio (10/14) Research conducted by Richard B. Hayes, DDS, MPH, PhD, professor in the Department of Population Health, and colleagues, indicates that oral bacteria linked to good hygiene may lower the risk of head and neck cancers, while those associated with periodontal disease may increase it; the study, which analyzed data from three U.S. cohorts, identified 22 bacterial species related to cancer risk, with bacteria such as Pyramidobacter piscolens and Lactobacillus paracollinoides increasing risk, and Simonsiella muelleri and Streptococcus sanguinis decreasing risk, though no fungal species were linked to these cancers.
5-FU Bolus Omission May Reduce Toxicity, Maintain Efficacy In GI Cancers. (Cancer Network)
Cancer Network (10/14) A real-world study published in the Journal of the National Comprehensive Cancer Network reveals that omitting the 5-fluorouracil bolus in multi-agent chemotherapy regimens for gastrointestinal cancer patients decreases toxicity without affecting overall survival, with Shun Yu, MD, clinical assistant professor in the Department of Medicine, Division of Hematology & Medical Oncology, emphasizing that this adjustment “makes the treatment more tolerable, potentially easing the chemotherapy experience for patients.”
Adult ADHD May Affect As Many As 1 In 4, According To New Survey. (Everyday Health)
Everyday Health (10/14) A national survey commissioned by The Ohio State University reveals that 25% of adults suspect they may have undiagnosed ADHD, but only about 1 in 8 discuss these concerns with a doctor, with social media contributing to increased self-diagnosis; Lenard A. Adler, MD, professor in the Department of Psychiatry and director of the Adult ADHD program at NYU Langone Health, indicates that post-pandemic data suggests 15.5 million U.S. adults report an ADHD diagnosis, half of whom were diagnosed in adulthood, emphasizing the disorder’s complexity and the importance of accurate diagnosis and treatment to avoid exacerbating symptoms similar to anxiety and depression.
